Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chebulinic acid
- Development stage
- Preclinical
- Lead developer
- CSIR-Central Drug Research Institute
- Modality
- Small Molecules
01
Overview
Chebulinic acid is a naturally occurring hydrolyzable tannin polyphenol isolated from medicinal plants such as *Terminalia chebula* and studied as an experimental small-molecule anticancer and antioxidant agent. Preclinical work, including the provided breast cancer study, suggests it can inhibit tumor cell proliferation and induce apoptosis, but its mechanism is not established as a single validated drug-target interaction; instead, reported activity is pleiotropic and likely related to polyphenolic modulation of oxidative stress, cell-cycle regulation, and apoptosis-associated signaling. It is not an approved pharmaceutical product, and current evidence supports it as a research-stage natural product rather than a clinically developed drug, with formulation work exploring nanoparticle delivery to improve exposure and antitumor activity in models of breast cancer.
- Other names
- chebulinic acid
02
Targets
CagA (Cytotoxin-associated gene A protein)DNA gyraseCD4 (T lymphocyte surface antigen)ORM1 (Alpha-1-acid glycoprotein 1)Mitogen-activated protein kinase/Extracellular signal-regulated kinase (MAPK/ERK) signaling pathway componentsHSA Site II (Human serum albumin Site II)
Beyond the preview
Go deeper on chebulinic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chebulinic acid.